首页> 外文期刊>BJS Open >Faecal immunochemical testing and blood tests for prioritization of urgent colorectal cancer referrals in symptomatic patients: a 2-year evaluation
【24h】

Faecal immunochemical testing and blood tests for prioritization of urgent colorectal cancer referrals in symptomatic patients: a 2-year evaluation

机译:粪便免疫化学测试和血液检测在症状患者中紧急结直肠癌的优先排序:2年评估

获取原文
           

摘要

Background A novel pathway incorporating faecal immunochemical testing (FIT) for rapid colorectal cancer diagnosis (RCCD) was introduced in 2017. This paper reports on the service evaluation after 2 years of pathway implementation. Methods The RCCD protocol was based on FIT, blood results and symptoms to stratify adult patients in primary care. Two-week-wait (2WW) investigation was indicated for patients with rectal bleeding, rectal mass and faecal haemoglobin (fHb) level of 10 μg Hb/g faeces or above or 4 μg Hb/g faeces or more in the presence of anaemia, low ferritin or thrombocytosis, in all other symptom groups. Patients with 100 μg Hb/g faeces or above had expedited investigation . A retrospective audit of colorectal cancer detected between 2017 and 2019 was conducted, fHb thresholds were reviewed and critically assessed for cancer diagnoses. Results In 2 years, 14788 FIT tests were dispatched with 13361 (90.4 per cent) completed returns. Overall, fHb was less than 4 μg Hb/g faeces in 9208 results (68.9 per cent), 4–9.9 μg Hb/g in 1583 (11.8 per cent), 10–99.9 μg Hb/g in 1850 (13.8 per cent) and 100 μg Hb/g faeces or above in 720 (5.4 per cent). During follow-up (median 10.4 months), 227 colorectal cancers were diagnosed. The cancer detection rate was 0.1 per cent in patients with fHb below 4 μg Hb/g faeces, 0.6 per cent in those with fHb 4–9.9 μg Hb/g faeces, 3.3 per cent for fHb 10–99.9 μg Hb/g faeces and 20.7 per cent for fHb 100 μg Hb/g faeces or above. The detection rate in the cohort with 10–19.9 μg Hb/g faeces was 1.4 per cent, below the National Institute for Health and Care Excellence threshold for urgent referral. The colorectal cancer rate in patients with fHb below 20 μg Hb/g faeces was less than 0.3 per cent. Conclusion Use of FIT to "rule out" urgent referral from primary care misses a small number of cases. The threshold for referral may be adjusted with blood results to improve stratification .
机译:背景技术2017年推出了一种具有快速结直肠癌诊断(RCCD)的粪便免疫化学测试(FIT)的新途径。本文报告了2年途径实施后的服务评估。方法rCCD协议基于拟合,血液效果和症状,在初级保健中分层成人患者。为患有直肠出血,直肠肿块和粪便血红蛋白(FHB)水平为10μgHB/ g粪便或以上或超过贫血的4μgHB/ g的患者,表明了两周的等待(2WW)调查。低铁蛋白或血小板减少,在所有其他症状群体中。患有100μgHB/ g粪便或以上的患者加快了调查。进行了2017年和2019年间检测到的结直肠癌的回顾性审计,审查了FHB阈值,并对癌症诊断进行了危重评估。结果2年来,14788年拟合试验拟订13361(90.4%)已完成回报。总体而言,FHB在9208个结果(68.9%)中,FHB少于4μgHB/ g粪便,在1583年(11.8%),1850年(13.8%),10-99.9μgHb/ g(13.8%)在720(5.4%)中,100μgHB/ g粪便或以上100μg。在随访期间(中位数10.4个月),诊断出227种结肠直肠癌。癌症检测率为4μgHB/ g粪便低于4μg的患者的癌症检出率为0.1%,在4-9.9μgHB/ g粪便中为0.6%,FHB10-99.9μg的3.3%,HB / g粪便对于FHB100μgHB/ g粪便或以上的20.7%。群组中的检出率为10-19.9μgHB/ g粪便为1.4%,低于国家健康和照顾卓越卓越门槛,急需推荐。 FHB低于20μgHB/ g粪便患者的结肠直肠癌率小于0.3%。结论使用适合“排除”初级保健的紧急转诊少数案件。可以用血液导致调整转介的阈值以改善分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号